Growth ⏱ Half-life: Mod-GRF (no DAC): approximately 30 minutes. CJC-1295 with DAC: approximately 8 days. The short half-life of Mod-GRF supports pulsatile dosing protocols that mimic natural GHRH release patterns.

CJC-1295

CJC-1295 (Modified GRF 1-29)

Buy from $42.99 →
Half-Life
Mod-GRF (no DAC): approximately 30 minutes. CJC-1295 with DAC: approximately 8 days. The short half-life of Mod-GRF supports pulsatile dosing protocols that mimic natural GHRH release patterns.
Mol. Weight
3367.97 g/mol

What is CJC-1295?

CJC-1295, commonly referred to as Modified GRF (1-29) or Mod-GRF, is a synthetic peptide analog of the body’s own growth hormone releasing hormone (GHRH). It stimulates the pituitary gland to produce and secrete growth hormone in a pulsatile, physiological manner.

Unlike exogenous growth hormone administration, CJC-1295 works with the body’s natural feedback mechanisms, amplifying endogenous GH pulses while preserving the natural rhythm of secretion. This has made it a popular compound in GH-axis research.

Research Applications

Research areas include:

  • GH axis stimulation: Pulsatile GH release, IGF-1 elevation studies
  • Body composition: Lean mass and fat metabolism research
  • Recovery and repair: Combined with GHRP peptides for tissue healing protocols
  • Sleep quality: GH pulse amplification during slow-wave sleep stages
  • Aging research: GH axis restoration in age-related decline models

Dosage Information (Research Use)

Published research protocols for CJC-1295 (no DAC / Mod-GRF):

  • Standard research dose: 100-300 mcg per administration
  • Frequency: 1-3 times daily (commonly before bed and/or upon waking)
  • Synergistic dosing: Typically combined with equimolar Ipamorelin (100 mcg CJC + 100 mcg Ipamorelin)
  • Timing: Best administered on empty stomach; fats and carbohydrates blunt GH release

Research use only.

Reconstitution & Handling

Standard reconstitution with BAC water. CJC-1295 dissolves readily. Store reconstituted peptide refrigerated.

Half-Life & Pharmacokinetics

Mod-GRF (no DAC): approximately 30 minutes. CJC-1295 with DAC: approximately 8 days. The short half-life of Mod-GRF supports pulsatile dosing protocols that mimic natural GHRH release patterns.

Reported Observations in Literature

Published observations include flushing and warmth at injection (common, transient), increased hunger, water retention, and numbness/tingling in extremities — all consistent with GH elevation effects.

Key Research References

  • Ionescu M, et al. “Stimulation of growth hormone secretion by CJC-1295.” J Clin Endocrinol Metab. 2006
  • Teichman SL, et al. “Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295.” J Clin Endocrinol Metab. 2006

How CJC-1295 Works

CJC-1295 (also called Modified GRF 1-29 or Mod-GRF) is a synthetic analog of growth hormone releasing hormone (GHRH) with four amino acid substitutions that confer DPP-IV resistance. It binds to GHRH receptors on pituitary somatotroph cells, stimulating the natural pulsatile release of growth hormone. Importantly, CJC-1295 amplifies existing GH pulses rather than creating a continuous non-physiological elevation, preserving the natural ultradian rhythm of GH secretion. This distinguishes it from exogenous GH administration.

Research Findings

Most commonly studied in combination with GHRP-type peptides (Ipamorelin, GHRP-2, GHRP-6) to achieve synergistic GH release. The GHRH + GHRP combination stimulates GH release through complementary pathways — GHRH receptor activation plus ghrelin/GHS receptor activation. The DAC (Drug Affinity Complex) version extends half-life to 8+ days via albumin binding, but most research uses the non-DAC (Mod-GRF) version for more physiological pulsatile dosing.

Dosage & Administration

Published research protocols for CJC-1295 (no DAC / Mod-GRF):

  • Standard research dose: 100-300 mcg per administration
  • Frequency: 1-3 times daily (commonly before bed and/or upon waking)
  • Synergistic dosing: Typically combined with equimolar Ipamorelin (100 mcg CJC + 100 mcg Ipamorelin)
  • Timing: Best administered on empty stomach; fats and carbohydrates blunt GH release

Research use only.

Safety & Side Effects

Published observations include flushing and warmth at injection (common, transient), increased hunger, water retention, and numbness/tingling in extremities — all consistent with GH elevation effects.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Molecular Weight 3367.97 g/mol
Half-Life Mod-GRF (no DAC): approximately 30 minutes. CJC-1295 with DAC: approximately 8 days. The short half-life of Mod-GRF supports pulsatile dosing protocols that mimic natural GHRH release patterns.
Available Sizes 2mg, 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C, use within 21 days.

Key Research References

  • Ionescu M, et al. "Stimulation of growth hormone secretion by CJC-1295." J Clin Endocrinol Metab. 2006
  • Teichman SL, et al. "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295." J Clin Endocrinol Metab. 2006

Get CJC-1295 from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Tesamorelin
Growth
Stabilized GHRH analog researched for visceral fat reduction, with clinical approval for HIV-associated lipodystrophy.
View Profile → Buy at SP →
CJC-1295 DAC
Growth
Long-acting GHRH analog with albumin-binding DAC extension for sustained GH elevation over 8+ days per injection.
View Profile → Buy at SP →
Hexarelin
Growth
Potent hexapeptide GH secretagogue with additional cardioprotective properties and direct cardiac receptor binding activity.
View Profile → Buy at SP →